AGN-199201 for the Treatment of Erythema With Rosacea
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of 3 doses of AGN-199201 once and twice
daily compared to vehicle for the treatment of moderate to severe facial erythema associated
with rosacea.